Skip to main content

RheumNow Podcast- Corona Increases RA Risk (3.13.20)

Mar 13, 2020 12:15 pm

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

  1. TNF inhibitors may slow, but do not stop, Xray progression in AS, Anti–IL-17A agents may maybe the same. Study by Inman et al shows that Tyk2 inhibition may prevent xray damage (animal model) by blocking IL-23 signaling and IL-22 production. https://t.co/OyyKoqdCl9
  2. CORRONA study of 24,528 #RA pts; 32% also has Sjogrens syndrome (overall SS prevalence in RA = 0.30 ). SS more likely with increasing RA duration, older, female, seropositive; higher DZ activity; more comorbidities and extra-articular manifestations https://t.co/EgTSzKHmtL
  3. Study of 179 RA pts, 21% with ILD, shows Anti-CarP Abs were strongly associated with ILD (OR 3.4). The role of homocitrullination in RA-ILD merits further investigation. https://t.co/F621UJ8Rex
  4. Rheumatic dz pts from British Columbia; compared 185 DMARD exposed Pregnancies vs 6,064 PREG NOT exposed. HCQ, AZA, SSZ before/during PREG not assoc w/ SGA births. 1st trimester MTX incr odds for congenital anomalies (aOR 6.58; 1.15-37.75). https://t.co/Kz5819lk1q
  5. UK population study shows that being over age 65 yrs increased the odds of receiving Seasonal influenza vaccination; but was without a reduction in hospitalizations or mortality among elderly persons. Call for new strategies https://t.co/viXwS5yx7W
  6. EHR analysis of two health systems on finds among 3,577 # RA pts; 507 smoked and 29% quit over 4.7 yrs. More likely to quit were new Care pts (aOR 1.60), and rural community health system pts (1.66); Seropositives were less likely to quit (0.57) https://t.co/gWcWoZpRVo
  7. 1 year results of the ustekinumab in SLE trial encouraging. 1st 6 mos DBRPCT showed UST 62% vs PBO 33%. At wk 48 UST SRI4 responses maintained 63.3%; PBO crossovers caught up. 15% had seriour adverse events. https://t.co/XauG4JOJIj
  8. Korean National Health claims study shows there was a significant increased risk of incident #RA 6-7 weeks following respiratory viral infections (parainfluenza, coronavirus, metapneumovirus), most evident in women and elderly. https://t.co/njXTGzdj7r
  9. EMA Final Recommendations on VTE Risk with Tofacitinib

 

Disclosures
The author has received compensation as an advisor or consultant on this subject

Add new comment

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

×